Wisevoter
World

Culture System Yields Billions of Immune Cells

National Cancer Institute researchers report a mouse bone marrow method that produces large numbers of CD103-positive cDC1 dendritic cells.

Updated on Nov. 4, 2026 in Cancer

Bold vector editorial illustration of clear glass culture flasks holding pale amber liquid with suspended cell clusters, one flask lifted to catch the light.
National Cancer Institute researchers report a bone marrow culture method that yields an estimated 1.5 billion CD103-positive cDC1 immune cells from a single mouse over 23 days. AI Illustration. Upload story photo >

Researchers at the National Cancer Institute developed a culture system that generates CD103-positive cDC1 dendritic cells from mouse bone marrow, reported in Myeloid Cells. The method produced an estimated 1.5 billion such cells from one mouse's bone marrow over a 23-day protocol.

Why it matters

Dendritic cells of this type help activate T cells and are central to immune research, but they have been difficult to obtain in large numbers. A reliable supply could support preclinical work in vaccine research and tumor immunology.

The study reports mouse-based culture yields of about 1.5 billion CD103-positive cDC1 cells per mouse, at least 75 times higher than prior recombinant cytokine approaches. Whether the method translates to human cells has not been established.

The players

National Cancer Institute

The National Cancer Institute is the U.S. federal agency within the National Institutes of Health that leads federal cancer research and funds studies on cancer biology and treatment.

The details

The 23-day protocol uses FLT3L, low-dose GM-CSF, and Kit ligand, with Kit ligand and GM-CSF acting together early in cDC1 generation. The resulting iDC1 cells cross-presented antigen to CD8-positive T cells and, in a transfer experiment, restored the response in two of four cDC1-deficient mice.

Timeline

  1. The culture protocol runs for 23 days.

Big Picture

Dendritic cell research has long been limited by how few cDC1 cells can be harvested from living animals. This culture method offers a route to larger preclinical supplies, though its applicability beyond mice is still untested.

For now the method is a laboratory tool rather than a treatment, so it does not change how patients access care. Its practical effect is limited to research labs working on immune cell biology.

The takeaway

A scalable way to produce cDC1 cells could speed up immune research that depends on these rare cells. Results still need to be confirmed in human systems before any clinical implications can be considered.

Further reading

Explore more cancer research coverage for context on immune cell therapies and tumor immunology.